Tech Company Financing Transactions
Aviir Funding Round
Aviir, based in Irvine, secured $30 million from Merck Capital Ventures, Aberdare Ventures and Bay City Capital.
Transaction Overview
Company Name
Announced On
12/20/2011
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Undisclosed
Investors
Merck Capital Ventures (Lead Investor)
Bay City Capital (William Gerber)
New Leaf Venture Partners (Vijay Lathi)
Proceeds Purpose
The proceeds will be used to fund commercialization of TruRisk(TM), Aviir's proprietary cardiac risk assessment technology, and additional molecular testing services provided through Aviir Heart Laboratories, based in Irvine, California.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9805 Research Dr.
Irvine, CA 92618
USA
Irvine, CA 92618
USA
Phone
Email Address
Not Recorded
Overview
Aviir is a venture-funded biotechnology company developing cutting-edge, convenient diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Harrington
Chief Financial Officer
Maria Messinger
Chief Operating Officer
Dan Angress
VP - Bus. Development
Najib Khoury
VP - Sales
Larry Hansen
Browse more venture capital transactions:
Prev: 12/20/2011: EnVerv venture capital transaction
Next: 12/20/2011: Matchbox venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs